Topol examines whether exceptional health span, or years lived in good health without disease or disability, can be traced to genetics. The Scripps “Wellderly” study (launched in 2008) identified about 1,400 adults aged 80+ who had never had a chronic illness and consented to whole-genome sequencing. The hypothesis—that distinctive genetic signatures would explain their extraordinary health—did not hold. Compared to the general population, the Wellderly group’s genomic risk markers for conditions like Alzheimer’s and heart disease were only marginally lower. What did distinguish them, on average, were non-genetic factors: They tended to be thinner by roughly 30 pounds, exercised more, had more education, and exhibited strikingly positive affect and social engagement (bridge clubs, dancing, volunteering, active circles of friends). The multiyear project therefore redirected attention from DNA alone to other drivers of healthy aging.

Topol contrasts this outlier cohort (which he nicknames the “Wellderly”) with the majority (nicknamed the “Illderly”). In the US, 60% of adults have at least one chronic disease and 40% have two or more; among those 65+, 80% have two or more. Achieving longevity accompanied by multiple chronic conditions is common; the more desirable aim is extending health span. Topol frames two routes forward: 1) preventing or delaying age-related diseases, and 2) slowing the aging process itself. The first path is already advancing; the second remains more challenging.

A central throughline of the chapter is the modern-day convergence of breakthroughs that recast chronic disease prevention and, potentially, aging biology itself. Topol argues that dysfunction and mis-calibration of the immune system is common to atherosclerosis, cancer progression, neurodegeneration, autoimmunity, and accelerated aging. However, new tools now enable finer “Goldilocks” modulation of inflammation. He surveys adjacent frontiers: microbiome manipulation (including FDA-approved fecal transplant for recurrent C. difficile); engineered T cells (CAR-T) for cancer, fibrosis, and autoimmune disease; individualized nutrition (NIH’s investment and AI-enabled “Diet 2.0”); next-generation cancer vaccines (including neoantigen approaches); and risk-stratified screening driven by multimodal data and AI. Topol then balances optimism with cautions about inequities, cost, regulatory barriers, model biases, and hype, emphasizing the need for diverse biobank resources and public investment.

The chapter concludes that, while anti-aging drugs remain nascent, the near-term, evidence-based path to becoming more “Wellderly” lies in materially improving primary prevention and early intervention against major age-related diseases.

Topol broadens the traditional concept of lifestyle—which typically refers to diet, exercise, sleep, and substance use—into a wider framework that incorporates environmental exposures, social factors, and behavioral patterns. He argues that many additional healthy years can be added without high-cost technologies by focusing on these expanded elements. The chapter reviews the strengths and limitations of evidence, noting that most diet, exercise, and sleep research comes from observational cohort studies, which reveal associations but not causation. Despite this, consistent patterns across large populations provide meaningful guidance. Randomized trials, though rarer, remain essential for establishing causality.

Topol highlights diet as a central pillar of health span. A global analysis linked poor diet to 22% of all deaths, surpassing tobacco and cancer as a cause of mortality. The prevalence of ultra-processed foods (UPFs)—foods engineered with additives and altered textures to promote overeating—has driven obesity, cardiovascular disease, metabolic disorders, and cognitive decline. Studies show strong dose-response relationships, with even modest increases in UPF consumption tied to higher risks of dementia, diabetes, and early death. Topol cites both large-scale reviews and small, controlled trials that underscore how UPFs disrupt gut-brain signaling and promote inflammation.

Other dietary components receive careful attention. High sugar consumption, particularly from sweetened beverages, is consistently tied to cardiovascular and cancer mortality, while artificial sweeteners show mixed evidence but raise concerns about microbiome disruption. Excess sodium increases cardiovascular and cognitive risks, though moderate intake appears tolerable. Carbohydrate quality (favoring-resistant starches and whole grains) is emphasized over quantity, while protein intake—especially in older adults—remains debated but increasingly linked to maintaining muscle mass. The quality of fats also matters, with plant-based unsaturated fats associated with longevity benefits, and evidence mounting in support of dairy and Mediterranean-style diets.

Beyond nutrition, Topol calls exercise the single most effective intervention for health span, conferring broad organ system benefits, reducing inflammation, and lowering all-cause mortality. Sleep is also described as essential for waste clearance in the brain and prevention of chronic disease, with seven hours per night identified as optimal. Finally, environmental toxins (pollution, plastics, noise, chemicals) and social determinants (isolation, socioeconomic inequities, food deserts) are presented as powerful, often under-recognized drivers of premature mortality. Collectively, these interdependent factors, grouped as lifestyle+, are a foundation for extending both lifespan and health span.